Aclaris Therapeutics (ACRS) Tops Q2 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.77 million versus the consensus estimate of $1.28 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Western Digital (WDC) call put ratio 1 call to 1 put as share price down 1.3%
• Micron Technology (MU) call put ratio 1.3 calls to 1 put as share price down 1%